MARKET

VNDA

VNDA

Vanda Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.49
-0.46
-2.71%
After Hours: 16.31 -0.18 -1.09% 17:58 09/20 EDT
OPEN
16.61
PREV CLOSE
16.95
HIGH
16.81
LOW
16.33
VOLUME
364.45K
TURNOVER
--
52 WEEK HIGH
21.86
52 WEEK LOW
9.00
MARKET CAP
917.47M
P/E (TTM)
28.54
1D
5D
1M
3M
1Y
5Y
Notable Vanda Pharmaceuticals Insider Trades $418.64 Thousand In Company Stock
Aranthan S. Jones Ii, Chief Corporate Affairs Officer at Vanda Pharmaceuticals (NASDAQ:VNDA), made a large buy and sell of company shares on September 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange C...
Benzinga · 3d ago
Insider Sell: Vanda Pharmaceuticals
MT Newswires · 3d ago
Uranium stocks are ripping higher as nuclear energy gets a second look
Uranium's on a tear. Here's how investors are getting in on the trade.
CNBC.com · 5d ago
Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the Citi 16 Annual BioPharma Virtual Conference taking place . Vanda management will host investor meetings. Vanda has updated its...
PR Newswire - PRF · 09/08 00:30
These are the two favorite trades of retail investors right now
Since last Tuesday, retail investors have bought more than $212 million shares of Advanced Micro Devices and $199 million shares AMC Entertainment.
CNBC.com · 09/03 15:46
5 Buy-Rated Small-Cap Biotech Stocks to Add to Your Watchlist
StockNews.com · 09/03 13:44
Sawgrass Asset Management Llc Buys Keysight Technologies Inc, Laboratory Corp of America ...
GuruFocus News · 08/20 16:38
Should Weakness in Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
It is hard to get excited after looking at Vanda Pharmaceuticals' (NASDAQ:VNDA) recent performance, when its stock has...
Simply Wall St. · 08/18 19:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VNDA. Analyze the recent business situations of Vanda Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VNDA stock price target is 24.00 with a high estimate of 24.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 256
Institutional Holdings: 68.59M
% Owned: 123.28%
Shares Outstanding: 55.64M
TypeInstitutionsShares
Increased
69
4.48M
New
14
887.50K
Decreased
62
4.39M
Sold Out
23
655.41K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Non-Executive Chairman/Independent Director
H. Thomas Watkins
Chief Executive Officer/President/Director
Mihael Polymeropoulos
Chief Financial Officer/Senior Vice President/Treasurer
Kevin Moran
Senior Vice President/Chief Marketing Officer
Joakim Wijkstrom
Senior Vice President/General Counsel/Secretary
Timothy Williams
Senior Vice President
Gunther Birznieks
Other/IR Contact Officer
Aranthan Jones
Independent Director
Phaedra Chrousos
Independent Director
Richard Dugan
Independent Director
Stephen Mitchell
Independent Director
Anne Ward
No Data
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

Webull offers kinds of Vanda Pharmaceuticals Inc. stock information, including NASDAQ:VNDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VNDA stock methods without spending real money on the virtual paper trading platform.